Eyck Freymann: How to Break China’s Minerals Chokehold
Why the allies need a multilateral commercial stockpile This essay is based on a Hoover History Lab working paper, co-authored with Joshua Stinson, William Norris,…
Thought Leader: Eyck Freymann
Covid Shows the Need for a Diagnostic Stockpile
By Scott Gottlieb and Mark McClellan (original source The Wall Street Journal)
“A surge in demand for Covid-19 tests is straining supplies, and patients have to wait too long for results. LabCorp, which handles about 25% of U.S. Covid testing, is adding more machines and employees and is running 180,000 tests a day, up from a few thousand a week in March. Quest and BioReference Laboratories are also overextended.
The ability to coordinate a surge in testing capacity is essential in a medical crisis. This isn’t the first time an epidemic has put stress on capabilities. In 2015, the mosquito-borne Zika infection strained the ability of public-health and commercial labs to develop and deploy tests, including for asymptomatic patients. Covid is much more widespread, and more testing is required since many with the virus show no symptoms.
Over the next few weeks, Congress will consider legislation to help get through the next phase of the pandemic. Lawmakers can alleviate the current shortages and shore up the ability to respond to future pandemics with adequate testing.”
Click here to read more
Relevant and recent posts
Chris Miller: Robotics Manufacturing: The Rise of Japan
“To the Americans, a robot is a computer attached to a mechanism. To Japanese, a robot is a mechanism attached to a computer.” The future…
Thought Leader: Chris Miller
Dr. Sanjay Gupta: A New Understanding of Parkinson’s Disease
Parkinson’s disease, a progressive movement disorder whose hallmark is damage to the dopamine-producing neurons in the brain, afflicts almost 12 million people worldwide. And the…
Thought Leader: Sanjay Gupta
More with this speaker
Scott Gottlieb on China’s biotech strategy
Thought Leader: Scott Gottlieb
Scott Gottlieb: China’s edge over U.S. biotech
Thought Leader: Scott Gottlieb